Liminatus Pharma, Inc. (NASDAQ:LIMN) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock (or pre-funded warrants) and accompanying warrants Announced: about US$4M · US$0.29 a share · Warrants at US$0.29 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Working capital, general corporate purposes and advancing the company's business objectives | Feb 17, 2026 |
| Strategic investment of newly issued shares Announced: US$30M Buyers: Capital Trust Group Limited (USD 30,000,000 equity financing via subscription for newly issued shares) Use of proceeds: Research and development of advanced immunotherapy assets | Oct 30, 2025 |
| Not stated Announced: up to US$500M · Digital Offering Dealers: Digital Offering (lead) Use of proceeds: Acquisition and long-term holding of BNB Coin through the planned American BNB Strategy subsidiary | Jul 28, 2025 |